Quest Partners LLC Immunovant, Inc. Transaction History
Quest Partners LLC
- $1.02 Trillion
- Q2 2025
A detailed history of Quest Partners LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 894 shares of IMVT stock, worth $24,593. This represents 0.0% of its overall portfolio holdings.
Number of Shares
894
Previous 5,700
84.32%
Holding current value
$24,593
Previous $97.4 Million
85.32%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding IMVT
# of Institutions
195Shares Held
79MCall Options Held
401KPut Options Held
354K-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.03MShares$193 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.88MShares$189 Million0.07% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.52% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$143 Million2.5% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...